Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Glaxosmithkline Biologicals Sa patents


Recent patent applications related to Glaxosmithkline Biologicals Sa. Glaxosmithkline Biologicals Sa is listed as an Agent/Assignee. Note: Glaxosmithkline Biologicals Sa may have other listings under different names/spellings. We're not affiliated with Glaxosmithkline Biologicals Sa, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "G" | Glaxosmithkline Biologicals Sa-related inventors


Adjuvanted formulations of booster vaccines

The invention improves tdap vaccines by including a tlr agonist in them. This agonist can provide stronger protection, longer-lasting protection, and/or can reduce the amount of antigen which is required to achieve a particular immune response.. ... Glaxosmithkline Biologicals Sa

Hybrid and tandem expression of neisserial proteins

Two or more neisserial proteins are joined such that they are translated as a single polypeptide chain. Hybrid proteins are represented by the formula nh2-a-[—x-l-]n—b—cooh where x is an amino acid sequence, l is an optional linker amino acid sequence, a is an optional n-terminal amino acid sequence, b is an optional c-terminal amino acid sequence, and n is an integer greater than 1. ... Glaxosmithkline Biologicals Sa

Combination vaccines with lower doses of antigen and/or adjuvant

Combination vaccine compositions as well as methods for their manufacture have a relatively low amount of antigen and/or a relatively low amount of aluminium, but they can nevertheless have immunogenicity which is comparable to combination vaccines with a relatively high amount of antigen and/or a relatively high amount of aluminium. Aluminium-free combination vaccine compositions are also provided e.g. ... Glaxosmithkline Biologicals Sa

Chlamydia antigens

The invention provides chlamydia antigens for use in the treatment, prevention and/or diagnosis of chlamydia infection. In particular, the invention provides antigens ct733, ct153, ct601, ct279, ct443, ct372, ct456, ct381, ct255, ct341, ct716, ct745, ct387, ct812, ct869, ct166, ct175, ct163, ct214, ct721, ct127, ct043, ct823 and/or ct600 from c. ... Glaxosmithkline Biologicals Sa

Vaccines for neisseria gonorrhoeae

Methods and compositions for immunizing a human subject against neisseria gonorrhoeae.. . ... Glaxosmithkline Biologicals Sa

Simian adenovirus nucleic acid-and amino acid-sequences, vectors containing same, and uses thereof

The present invention relates to novel adenovirus strains with an improved seroprevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. ... Glaxosmithkline Biologicals Sa

Immunogenic compositions

A method of immunization against group b streptococcus infection, using an immunogenic composition conjugates of gbs capsular saccharide conjugated to carrier proteins.. . ... Glaxosmithkline Biologicals Sa

Multiple variants of meningococcal protein nmb1870

Meningococcal protein nmb 1870 has been described in the prior art. The inventors have found that nmb 1870 is an effective antigen for eliciting anti-meningococcal antibody responses, and that it is expressed across all meningococcal serogroups. ... Glaxosmithkline Biologicals Sa

Immunogenic bacterial vesicles with outer membrane proteins

Knockout of the meningococcal mlta homolog gives bacteria that spontaneously release vesicles that are rich in immunogenic outer membrane proteins and that can elicit cross-protective antibody responses with higher bactericidal titres than omvs prepared by normal production processes. Thus the invention provides a bacterium having a knockout mutation of its mlta gene. ... Glaxosmithkline Biologicals Sa

Adjuvanting meningococcal factor h binding protein

Factor h binding protein (fhbp) has been proposed for use in immunising against serogroup b meningococcus (‘menb’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a ph which is equal to or below the adjuvant's point of zero charge (pzc), and/or (ii) selecting a fhbp and adjuvant with an isoelectric point/pzc within the range of 5.0 to 7, and/or (iii) selecting a fhbp with an isoelectric point above the adjuvant's pzc and using a buffer to bring the ph to within 1.2 ph units of the pzc. ... Glaxosmithkline Biologicals Sa

Purification of streptococcal capsular polysaccharide

A purification method for the capsular polysaccharide of type ii gbs in which the capsular polysaccharide is filtered using a membrane with a cut-off of less than 30 kda.. . ... Glaxosmithkline Biologicals Sa

Compositions for immunising against staphylococcus aureus

An effective staphylococcus aureus vaccine may require several antigenic components, and so various combinations of s. Aureus antigens are identified for use in immunisation. ... Glaxosmithkline Biologicals Sa

Multiple variants of meningococcal protein nmb1870

Meningococcal protein nmb 1870 has been described in the prior art. The inventors have found that nmb 1870 is an effective antigen for eliciting anti-meningococcal antibody responses, and that it is expressed across all meningococcal serogroups. ... Glaxosmithkline Biologicals Sa

Method of treatment

The application discloses a method of immunising against staphylococcus aureus infection comprising a step of administering to a human patient a single dose of an immunogenic composition comprising; (i) a staphylococcus aureus clfa protein or immunogenic fragment thereof at a dose of 5-50, 10-30, 5-15 or 20-40 μg and (ii) a pharmaceutically acceptable excipient; wherein the ph of the composition is ph 5.0-ph 8.0. The application further discloses an immunogenic composition comprising; (i) a s. ... Glaxosmithkline Biologicals Sa

08/31/17 / #20170246290

Oil-in-water emulsion influenza vaccine

The present invention provides an immunogenic influenza composition in a dose volume suitable for human use, comprising an influenza virus antigen or antigenic preparation thereof and an adjuvant composition comprising an oil-in-water emulsion, wherein said oil-in-water emulsion comprises a metabolisable oil at a level of below 11 mg and an emulsifying agent at a level of below 5 mg and optionally a tocol or a sterol at a level of below 12 mg. Suitably the amount of influenza antigen per strain per dose is 15 μg ha or a low amount such as less than 15 μg ha.. ... Glaxosmithkline Biologicals Sa

08/31/17 / #20170246285

Conjugation of streptococcal capsular saccharides

Three conjugation methods for use with the capsular saccharide of streptococcus agalactiae. In the first method, reductive amination of oxidized sialic acid residue side chains is used, but the aldehyde groups are first aminated, and then the amine is coupled to a carrier via a linker. ... Glaxosmithkline Biologicals Sa

08/10/17 / #20170224803

Carrier molecule for antigens

The invention provides a conjugate comprising an antigen and a carrier molecule, wherein the carrier molecule comprises a bp-2a antigen and a spb1 antigen. Bp-2a and spb1 are streptococcus agalactiae antigens. ... Glaxosmithkline Biologicals Sa

08/10/17 / #20170224616

Oil-in-water emulsions that contain nucleic acids

This invention generally relates to cationic oil-in-water emulsions that can be used to deliver nucleic acid molecules, such as an rna molecule. The emulsion particles comprise an oil core and a cationic lipid. ... Glaxosmithkline Biologicals Sa

08/03/17 / #20170218031

Clostridium difficile immunogenic composition

Immunogenic compositions comprising isolated clostridium difficile cdtb proteins, including modified proteins, and fusion proteins comprising a cdta protein and a cdtb protein.. . ... Glaxosmithkline Biologicals Sa

06/15/17 / #20170165346

Combination neisserial compositions

Compositions comprising a first biological molecule from a neisseria bacterium and a second biological molecule from a neisseria bacterium. The term “biological molecule” includes proteins and nucleic acids. ... Glaxosmithkline Biologicals Sa

05/18/17 / #20170137475

Expression system

Compositions and methods related to periplasmic expression of a toxin including diphtheria toxin or crm197 are provided herein.. . ... Glaxosmithkline Biologicals Sa

05/18/17 / #20170136110

Novel methods for inducing an immune response

Methods and uses are provided for inducing an immune response comprising at least two administrations of an immunogenic composition, wherein a lower dose is given in the second administration than in the first administration, and wherein the second administration may be unadjuvanted.. . ... Glaxosmithkline Biologicals Sa

05/04/17 / #20170119868

Adjuvanting meningococcal factor h binding protein

Factor h binding protein (fhbp) has been proposed for use in immunising against serogroup b meningococcus (‘menb’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a ph which is equal to or below the adjuvant's point of zero charge (pzc), and/or (ii) selecting a fhbp and adjuvant with an isoelectric point/pzc within the range of 5.0 to 7, and/or (iii) selecting a fhbp with an isoelectric point above the adjuvant's pzc and using a buffer to bring the ph to within 1.2 ph units of the pzc. ... Glaxosmithkline Biologicals Sa

04/20/17 / #20170106070

Uses of parasite macrophage migration inhibitory factors

This invention relates to compositions (e.g. Vaccine compositions) which can be used to provide a subject with protective immunity against a parasite infection. ... Glaxosmithkline Biologicals Sa

04/13/17 / #20170100472

Combination vaccines with serogroup b meningococcus and d/t/p

Serogroup b meningococcus antigens can successfully be combined with diphtheria, tetanus and pertussis toxoids (“dtp”) to provide effective combination vaccines for protecting against multiple pathogens. These combinations are effective with a range of different adjuvants, and with both pediatric-type and booster-type dtp ratios. ... Glaxosmithkline Biologicals Sa

03/23/17 / #20170080084

Oil/surfactant mixtures for self-emulsification

Oil-in-water emulsions with small droplet sizes can be formed without requiring either microfluidisation or heating to cause phase inversion, but rather by simple mixing of a pre-mixed composition of oil and a surfactant component comprising at least one surfactant component with aqueous material. The hlb value of the surfactant component can be selected to give a composition which, on mixing with a volume excess of aqueous material, spontaneously forms an oil in water emulsion with submicron oil droplets having a diameter <250 nm, suitable for filter sterilisation. ... Glaxosmithkline Biologicals Sa

03/23/17 / #20170080077

Heterologous expression of neisserial proteins

Alternative and improved approaches to the heterologous expression of the proteins of neisseria meningitidis and neisseria gonorrhoeae are disclosed. These approaches typically affect the level of expression, the ease of purification, the cellular localization, and/or the immunological properties of the expressed protein.. ... Glaxosmithkline Biologicals Sa

03/23/17 / #20170080076

Heterologous expression of neisserial proteins

Alternative and improved approaches to the heterologous expression of the proteins of neisseria meningitidis and neisseria gonorrhoeae are disclosed. These approaches typically affect the level of expression, the ease of purification, the cellular localization, and/or the immunological properties of the expressed protein.. ... Glaxosmithkline Biologicals Sa

03/16/17 / #20170073716

Purification of secreted polysaccharides from s. agalactiae

The invention relates to bacterial mutants, particularly from streptococcus agalactiae, that secrete capsular polysaccharide and methods of purifying the secreted bacterial capsular polysaccharides from culture medium. The extracted polysaccharides are useful for producing vaccines comprising the polysaccharides alone or conjugated to proteins.. ... Glaxosmithkline Biologicals Sa

02/16/17 / #20170044571

Chimpanzee adenoviral vector-based filovirus vaccines

This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of ebolavirus (ebov) or marburg virus (marv).. ... Glaxosmithkline Biologicals Sa

02/16/17 / #20170043004

Capsular polysaccharide solubilisation and combination vaccines

Precipitated bacterial capsular polysaccharides can be efficiently re-solubilised using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilisation of the precipitated polysaccharide using ethanol. ... Glaxosmithkline Biologicals Sa

01/12/17 / #20170008933

Modified meningococcal fhbp polypeptides

Modified meningococcal fhbp polypeptides with increased stability.. . ... Glaxosmithkline Biologicals Sa

01/12/17 / #20170008932

Uspa2 protein constructs and uses thereof

The present invention relates to compositions comprising moraxella catarrhalis (m. Catarrhalis) ubiquitous surface protein a2 (uspa2). ... Glaxosmithkline Biologicals Sa








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Glaxosmithkline Biologicals Sa in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Glaxosmithkline Biologicals Sa with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###